A
Alcista
Alcista · 25%ORIC
$12.31
Precio del escenario
$12.350
-0.406 (-3.29%)Al cierre
Loading chart…
- Máximo
- 12.750
- Apertura
- 12.750
- Precio medio ponderado por volumen
- 12.38
- Volumen
- 946.20K
- Capitalización
- 465.89M
- Mínimo
- 12.025
- Importe
- 11.71M
- EV/EBITDA, TTM
- 0.00
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Análisis de IA of Oric Pharmaceuticals Inc (ORIC)
ComprarOric Pharmaceuticals Inc (ORIC) is a good buy right now due to its current price of $12.35, which is significantly lower than the average analyst price target of $26. Additionally, the stock has shown a year-to-date change of +51.16%, indicating strong momentum. However, it is important to note that the company reported a net loss of $41.49 million in Q2 2026, which is a risk to consider.
Métricas de valoración
El PER previsto actual de Oric Pharmaceuticals Inc (ORIC) es 0.00, frente a su media de 5 años de -4.22.
Escenarios de precio de Alphio AI para ORIC
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con ORIC en cartera
Cronología de eventos
Noticias
5.009-04NewsfilterORIC Pharmaceuticals Grants Stock Options to New Employees
5.008-07GlobenewswireORIC Pharmaceuticals Grants Stock Options to New Employees
- 5.008-07Newsfilter
ORIC Pharmaceuticals Grants Stock Options to New Employees
9.508-04NASDAQ.COMORIC Pharmaceuticals Reports Wider Q2 Net Loss and Pipeline Updates
9.508-03seekingalphaORIC Pharmaceuticals Q2 Earnings Report Analysis
Preguntas frecuentes sobre ORIC, respondidas por Alphio AI
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Oric Pharmaceuticals Inc (ORIC) is a good buy right now due to its current price of $12.35, which is significantly lower than the average analyst price target of $26. Additionally, the stock has shown a year-to-date change of +51.16%, indicating strong momentum. However, it is important to note that the company reported a net loss of $41.49 million in Q2 2026, which is a risk to consider.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.